RU2008120027A - Анти-addl моноклональное антитело и его применение - Google Patents
Анти-addl моноклональное антитело и его применение Download PDFInfo
- Publication number
- RU2008120027A RU2008120027A RU2008120027/13A RU2008120027A RU2008120027A RU 2008120027 A RU2008120027 A RU 2008120027A RU 2008120027/13 A RU2008120027/13 A RU 2008120027/13A RU 2008120027 A RU2008120027 A RU 2008120027A RU 2008120027 A RU2008120027 A RU 2008120027A
- Authority
- RU
- Russia
- Prior art keywords
- diffusing
- ligands
- derivatives
- xaa
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2005381125 | 2005-10-21 | ||
| USPCT/US2005/038125 | 2005-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008120027A true RU2008120027A (ru) | 2009-11-27 |
Family
ID=39671607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008120027/13A RU2008120027A (ru) | 2005-10-21 | 2006-10-17 | Анти-addl моноклональное антитело и его применение |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1940466B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5289963B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101291692A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006306553B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2626783A1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20082288L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008120027A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007050359A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| HRP20150086T1 (xx) * | 2007-06-12 | 2015-02-27 | Ac Immune S.A. | Humanizirana antitijela za beta amiloid |
| PL2238166T3 (pl) | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| EP2586797A3 (en) * | 2007-11-27 | 2013-07-24 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
| JP5529869B2 (ja) * | 2008-08-14 | 2014-06-25 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインaアフィニティークロマトグラフィーを用いる抗体の精製方法 |
| EP2510359B1 (en) | 2009-12-11 | 2015-09-02 | Araclón Biotech, S. L. | Methods and reagents for improved detection of amyloid beta peptides |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9320793B2 (en) | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| US20130115227A1 (en) * | 2010-07-14 | 2013-05-09 | Renee C. Gaspar | Anti-addl monoclonal antibody and uses thereof |
| US9176151B2 (en) | 2010-07-14 | 2015-11-03 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
| CN103782171B (zh) * | 2011-07-13 | 2016-12-14 | 默沙东公司 | 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途 |
| JP6231263B2 (ja) * | 2012-07-17 | 2017-11-15 | 株式会社島津製作所 | アフィニティ支持体及びそれを用いた物質の捕捉方法 |
| CN106661103B (zh) | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0683234B2 (en) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
| US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| SI0994728T1 (sl) * | 1997-04-09 | 2009-02-28 | Intellect Neurosciences Inc | Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo |
| JP2006508072A (ja) * | 2002-10-01 | 2006-03-09 | ノースウエスタン ユニバーシティ | アミロイドベータ由来拡散性リガンド(ADDLs)、ADDL代替物、ADDL結合性分子、およびそれらの使用 |
| TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| KR20070094890A (ko) * | 2004-10-25 | 2007-09-27 | 머크 앤드 캄파니 인코포레이티드 | 안티 addl 항체 및 그 용도 |
-
2006
- 2006-10-17 AU AU2006306553A patent/AU2006306553B9/en not_active Expired - Fee Related
- 2006-10-17 WO PCT/US2006/040508 patent/WO2007050359A2/en not_active Ceased
- 2006-10-17 RU RU2008120027/13A patent/RU2008120027A/ru not_active Application Discontinuation
- 2006-10-17 JP JP2008536730A patent/JP5289963B2/ja active Active
- 2006-10-17 EP EP06836346A patent/EP1940466B1/en active Active
- 2006-10-17 CN CNA2006800392637A patent/CN101291692A/zh active Pending
- 2006-10-17 CA CA002626783A patent/CA2626783A1/en not_active Abandoned
-
2008
- 2008-05-19 NO NO20082288A patent/NO20082288L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2626783A1 (en) | 2007-05-03 |
| AU2006306553B9 (en) | 2011-09-29 |
| JP2009519895A (ja) | 2009-05-21 |
| EP1940466A2 (en) | 2008-07-09 |
| EP1940466B1 (en) | 2012-11-28 |
| JP5289963B2 (ja) | 2013-09-11 |
| AU2006306553A1 (en) | 2007-05-03 |
| WO2007050359A2 (en) | 2007-05-03 |
| WO2007050359A8 (en) | 2008-05-08 |
| CN101291692A (zh) | 2008-10-22 |
| EP1940466A4 (en) | 2010-04-07 |
| AU2006306553B2 (en) | 2011-08-25 |
| WO2007050359A3 (en) | 2007-06-21 |
| NO20082288L (no) | 2008-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fujii et al. | D-Amino acids in protein: The mirror of life as a molecular index of aging | |
| RU2013106270A (ru) | Моноклональное антитело против addl и его применения | |
| EP2749646B1 (en) | IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME | |
| US6319897B1 (en) | Peptides which inhibit complement activation | |
| Arnon et al. | Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate | |
| JP2009519895A5 (cg-RX-API-DMAC7.html) | ||
| RU2014102007A (ru) | Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов | |
| JPWO2003085399A1 (ja) | 白血病、前白血病または非白血病性悪性血液疾患の判定方法及び診断薬 | |
| WO2016032949A1 (en) | Targeting immunotherapy for amyloidosis | |
| RU2017103527A (ru) | ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β(Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| US20070128191A1 (en) | Polyclonal antibodies, preparation method thereof and use of same | |
| ES2201929B1 (es) | Anticuerpos policlonales, metodo de preparacion y uso de los mismos. | |
| EP0752425B1 (en) | Peptide ligands for the constant region of immunoglobulins | |
| US11104705B2 (en) | Methods for removing bacterial toxins from a biological fluid | |
| Katsoyannis et al. | [47] The synthesis of peptides by homogeneous solution procedures | |
| AU2016344146A1 (en) | Methods of measuring Factor D activity and potency of Factor D inhibitors | |
| US7074765B2 (en) | Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 | |
| Galati et al. | Increased resistance of peptides to serum proteases by modification of their amino groups | |
| CA2518066A1 (en) | Diagnosis of autism | |
| JP2000221191A (ja) | ヒト障害についての診断マ―カ― | |
| KR930703444A (ko) | 어류 황체화 호르몬-방출 호르몬 동족체 | |
| CA2488127A1 (en) | Antibodies directed against prothrombin fragment f1+2, the preparation and use thereof | |
| JP2000186100A (ja) | レニン活性物質 | |
| US20120070907A1 (en) | Method to deplete monoclonal antibodies in a biological sample | |
| ITMI952582A1 (it) | Peptidi antigenici migliorati |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100312 |